Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration

Invivyd has dosed the first participants in LIBERTY, a Phase 3 clinical trial evaluating the safety and tolerability of its monoclonal antibody candidate VYD2311 versus mRNA COVID-19 vaccines. The trial will enroll approximately 210 healthy adults across three arms: VYD2311 alone, mRNA vaccine alone, and co-administration of both. This head-to-head design aims to characterize VYD2311 as a more tolerable alternative to traditional vaccination. Invivyd expects to report topline data from LIBERTY in Q3 2026, coinciding with anticipated data from its pivotal DECLARATION efficacy trial.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.